<DOC>
	<DOCNO>NCT00757549</DOCNO>
	<brief_summary>RATIONALE : Diagnostic procedure , 3'-deoxy-3'- [ 18F ] fluorothymidine ( FLT ) fludeoxyglucose F 18 ( FDG ) PET scan , may help doctor predict patient 's response treatment help plan best treatment . PURPOSE : This pilot trial study FLT FDG PET scan see well evaluate response cetuximab , cisplatin , radiation therapy patient advance cancer oropharynx , larynx , hypopharynx .</brief_summary>
	<brief_title>3'-Deoxy-3'-18F Fluorothymidine Fludeoxyglucose F 18 PET Scans Evaluating Response Cetuximab , Cisplatin , Radiation Therapy Patients With Advanced Cancer Oropharynx , Larynx , Hypopharynx</brief_title>
	<detailed_description>OBJECTIVES : Primary - To assess whether 3'-deoxy-3'- [ 18F ] fluorothymidine ( FLT ) fludeoxyglucose F 18 ( FDG ) PET scan use identify patient advance squamous cell carcinoma oropharynx , larynx , hypopharynx biochemical response 2 week induction therapy cetuximab . - To assess whether FLT FDG PET imaging-based response 20-30 Gy radiotherapy predictive disease control 6 month completion therapy . Secondary - To assess whether FLT FDG PET imaging-based response cetuximab therapy and/or 20-30 Gy radiotherapy predictive pathologic complete response patient . - To assess whether FLT FDG PET imaging-based response cetuximab therapy and/or 20-30 Gy radiotherapy predictive disease-free survival 2 year patient . - To correlate suppression FLT uptake cetuximab therapy thymidine kinase 1 activity and/or expression , proliferation , microvessel density , apoptosis , signal pathway analysis . - To correlate suppression FDG uptake cetuximab therapy expression hexokinases , glucose transporter proliferation , microvessel density , apoptosis , signal pathway analysis . - To test refine ability novel commercial software package quantify treatment-induced structural functional/molecular volumetric sub-volumetric change . - To develop work method express change predict outcome . OUTLINE : Patients receive cetuximab IV day 1 8 course 1 . Beginning course 2 subsequent course , patient receive cetuximab IV cisplatin IV 2 hour day 1 undergo radiotherapy daily 5 day week 7 week . Treatment repeat every 7 day total 8 course absence disease progression unacceptable toxicity . Patients undergo 3'-deoxy-3'- [ 18F ] fluorothymidine fludeoxyglucose F 18 ( FDG ) PET scan baseline , second dose cetuximab , 20-30 Gy radiotherapy , 6 week 6 month completion radiotherapy . Patients undergo tumor tissue biopsy baseline first dose cetuximab correlative laboratory study . Samples analyze proliferation ( Ki-67 label index ) , microvessel density ( CD-31 staining ) , apoptosis ( TUNEL assay caspase-3 IHC ) signal pathway ( expression EGFR , AKT , MAPK IHC ) , molecules affect FDG uptake ( expression GLUT1 , GLUT3 , hexokinase IHC ) , thymidine kinase 1 activity expression . After completion study treatment , patient follow every 3 month 5 year .</detailed_description>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<mesh_term>Dideoxynucleosides</mesh_term>
	<mesh_term>Alovudine</mesh_term>
	<mesh_term>Fluorodeoxyglucose F18</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm squamous cell carcinoma oropharynx , larynx , hypopharynx Advanced disease Requires chemoradiotherapy PATIENT CHARACTERISTICS : ECOG performance status 01 Life expectancy ≥ 16 week Weight loss ≤ 10 % within past 3 month Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception ANC ≥ 1,500/mm³ Platelet count ≥ 100,000/mm³ Total bilirubin ≤ 1.5 time upper limit normal ( ULN ) AST ≤ 3 time ULN Hemoglobin ≥ 8 g/dL Creatinine clearance ≥ 40 mL/min No peripheral neuropathy ≥ grade 2 No NYHA class IIIIV heart disease No uncontrolled infection No poorly control diabetes would limit ability obtain reliable fludeoxyglucose F 18 PET scan result No severe underlie disease , judgment investigator , would preclude study participation PRIOR CONCURRENT THERAPY : More 2 week since prior major surgery recover No prior radiotherapy planned treatment field No concurrent prophylactic filgrastim ( GCSF ) sargramostim ( GMCSF )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>recurrent squamous cell carcinoma hypopharynx</keyword>
	<keyword>recurrent squamous cell carcinoma larynx</keyword>
	<keyword>recurrent squamous cell carcinoma oropharynx</keyword>
	<keyword>stage III squamous cell carcinoma hypopharynx</keyword>
	<keyword>stage III squamous cell carcinoma larynx</keyword>
	<keyword>stage III squamous cell carcinoma oropharynx</keyword>
	<keyword>stage IV squamous cell carcinoma hypopharynx</keyword>
	<keyword>stage IV squamous cell carcinoma larynx</keyword>
	<keyword>stage IV squamous cell carcinoma oropharynx</keyword>
</DOC>